| Abstrakt: |
A new study conducted at the University of Naples Federico II in Italy has examined the real-life effectiveness and safety of guselkumab, a monoclonal antibody used to treat psoriasis in patients who have not responded well to ustekinumab. The study followed 112 patients over a period of up to 3 years and found that guselkumab was effective in improving psoriasis symptoms and had no serious adverse effects. However, the presence of psoriatic arthritis or palmoplantar psoriasis was associated with reduced improvement in symptoms. Overall, the study confirmed the long-term efficacy and safety of guselkumab in this patient population. [Extracted from the article] |
